Home - Blank Rome LLP

Register to receive insights and analyses on breaking news and trends across varying industries.
<a class="link-primary mt-4" href="/subscribe">Subscribe</a>

Philadelphia, PA

New York, NY

Wilmington, DE

Cincinnati, OH

Princeton, NJ

Los Angeles, CA

Houston, TX

Tampa, FL

Shanghai

South Florida

Pittsburgh, PA

Washington, D.C.

Chicago, IL

Orange County, CA

Dallas, TX

Boston, MA

Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide injections and pills infringe on its patent covering the active pharmaceutical ingredient semaglutide, which is currently available in commercial form as Ozempic®, Wegovy®, and Rybelsus®. According to the complaint, all compounded versions of drugs containing semaglutide unlawfully incorporate the patented ingredient and circumvent the Food and Drug Administration’s (“FDA”) new drug approval process. Novo Nordisk is seeking a permanent injunction and damages, among other forms of relief.&nbsp;

core/paragraph

The Blank Rome regulatory, intellectual property, and litigation teams are closely monitoring these developments. Recent regulatory actions and this newly filed litigation reflect increased federal attention to compounded GLP‑1 drugs, and the legal and enforcement landscape remains dynamic. Our teams are actively monitoring these developments and are available to help clients evaluate what these evolving developments may mean for ongoing operations and risk management in the prescribing, compounding, and dispensing of GLP‑1s as well as promotion and marketing.&nbsp;

For more information or assistance, please contact&nbsp;<a href="https://www.blankrome.com/people/rachael-g-pontikes">Rachael G. Pontikes</a>,&nbsp;<a href="https://www.blankrome.com/people/emily-l-hussey">Emily Hussey</a>,&nbsp;<a href="https://www.blankrome.com/people/shannon-e-mcclure">Shannon E. McClure</a>,&nbsp;<a href="https://www.blankrome.com/people/domingo-manuel-llagostera">Domingo Manuel Llagostera</a>,&nbsp;<a href="https://www.blankrome.com/people/jay-p-lessler">Jay P. Lessler</a>,&nbsp;<a href="https://www.blankrome.com/people/ferlillia-v-roberson">Ferlillia V. Roberson</a>, or another member of Blank Rome’s&nbsp;<a href="https://www.blankrome.com/services-and-industries/healthcare">Healthcare</a>,&nbsp;<a href="https://www.blankrome.com/services-and-industries/litigation/business-litigation">Business Litigation</a>, or&nbsp;<a href="https://www.blankrome.com/services-and-industries/intellectual-property-litigation">Intellectual Property Litigation</a>&nbsp;groups.

core/button

core/buttons

Download This Alert

Healthcare

Rachael G. Pontikes

Emily L. Hussey

Shannon E. McClure

Domingo Manuel LLagostera

Jay P. Lessler

Business Litigation

Intellectual Property Litigation

Alert

Publications

Novo Nordisk Files Patent Infringement Suit Involving Compounded Semaglutide Products

Novo Nordisk Files Patent Infringement Suit Involving Compounded Semaglutide Products

Offices

Stay Connected

Slide Menu

Slide Search

Novo Nordisk Files Patent Infringement Suit Involving Compounded Semaglutide Products

Offices

Stay Connected